Hypoadiponectinemia in overweight children contributes to a negative metabolic risk profile 6 years later

Iben Kynde1, Berit L Heitmann, Ib C Bygbjerg

  • 1Department of Biomedical Sciences, Centre for Healthy Ageing, University of Copenhagen, 2200 Copenhagen, Denmark. ibenk@mfi.ku.dk

Insights

Low adiponectin and high leptin in childhood indicate higher cardiometabolic risk. Plasma adiponectin may identify overweight children at future risk.

Area of Science:

  • Pediatric endocrinology
  • Cardiovascular health
  • Metabolic syndrome research

Background:

  • Cardiometabolic risk in children requires prognostic biomarkers.
  • Metabolic and inflammatory markers' association with risk factors is understudied.

Purpose of the Study:

  • To investigate associations between plasma adiponectin, leptin, interleukin-8, and hepatocyte growth factor and cardiometabolic risk factors in children and adolescents.
  • To determine if these markers predict future cardiometabolic risk, particularly in overweight children.

Main Methods:

  • Cross-sectional and prospective study (European Youth Heart Studies I and II).
  • Baseline assessment of 256 children (8-10 years) and 6-year follow-up of 169.
  • Cardiometabolic risk score calculated from BMI, insulin resistance, cholesterol ratio, triglycerides, blood pressure, and fitness; plasma markers assessed via immunochemical assays.

Main Results:

  • Inverse association between metabolic risk score and plasma adiponectin (P=.02), and positive association with plasma leptin (P<.0001) at baseline.
  • In overweight children, baseline plasma adiponectin inversely associated with metabolic risk score at follow-up (P=.04).
  • Hypoadiponectinemia and hyperleptinemia in childhood correlate with adverse metabolic profiles.

Conclusions:

  • Childhood hypoadiponectinemia and hyperleptinemia are linked to negative cardiometabolic risk profiles.
  • Plasma adiponectin shows potential as a biomarker for identifying overweight children at higher future cardiometabolic risk.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...